# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RD01 (Pegerythropoietin) in Healthy Chinese Volunteers

> **NCT03657238** · PHASE1 · COMPLETED · sponsor: **Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd** · enrollment: 84 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** RD01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03657238
- **Lead sponsor:** Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-08
- **Primary completion:** 2019-08-02
- **Final completion:** 2019-08-02
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2020-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03657238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03657238, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RD01 (Pegerythropoietin) in Healthy Chinese Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03657238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*